21.8 C
New York
Wednesday, June 10, 2026

Tag: population

newssourceFORcompanyinformationcontent1marketreleases

Charlotte Volsch, Apple Valley, California Broker, Named Among Real Trends 2026 Best Real Estate Agents in the United States by RealTrends Verified | #1826...

Inland Empire and High Desert Probate and Trust Real Estate Specialist Ranks in the Top 1% of California Realtors 
Inland Empire and High Desert Probate and Trust Real Estate Specialist Ranks in the Top 1% of California Realtors

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

PRESS RELEASE

The Jackson Laboratory secures grant from The Michael J. Fox Foundation to advance Parkinson’s disease research through the JAX-NYSCF Collaborative

New human stem cell platform will expand access to standardized disease models, support Parkinson's disease research and therapeutic discovery efforts NEW YORK , June 9,...

VEON Appoints Serkan Ozturk as Chief of Staff & Strategy Officer

Dubai and New York, June 9, 2026 — VEON Ltd. (NASDAQ: VEON), a global digital operator (the “Company” or “VEON”), today announces the appointment of Serkan Ozturk as Chief of Staff & Strategy Officer, effective June 9, 2026.

VenHub Global Expands Autonomous Retail Platform into Florida

VenHub enters the Florida market through a new operator-led deployment model, marking a key step in its U.S. commercial rollout 
VenHub enters the Florida market through a new operator-led deployment model, marking a key step in its U.S. commercial rollout

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

June 9, 2026
Announcement no. 12

Supported by Huawei, Aztelekom Achieves Near Nationwide Broadband Connectivity through “Online Azerbaijan”

BAKU, Azerbaijan, June 9, 2026 /PRNewswire/ -- Aztelekom, a part of AZCON Holding company, and Huawei announced today that the nation's "Online Azerbaijan" broadband...

Duke-NUS awarded €2 million EU grant to help Asia detect outbreaks earlier through wastewater surveillance

EU-funded project will help countries build early-warning systems to spot infectious disease threats before clinical cases surge SINGAPORE, June 9, 2026 /PRNewswire/ -- Duke-NUS...

PPMW launches summer Spill the Tea ambassadorship for Black Women

WASHINGTON, June 8, 2026 /PRNewswire/ -- In May, Planned Parenthood of Metropolitan Washington, DC launched the most recent cohort of its Spill the Tea...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion...

Châtillon, France, le 8 juin (22 :30 CET) 2026

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

CDC Foundation Activates Emergency Response Fund to Support Ebola Response in Democratic Republic of the Congo and Uganda

Flexible Funding Needed to Support the Global Response and Frontline Efforts ATLANTA, June 8, 2026 /PRNewswire/ -- As the Ebola outbreak caused by Bundibugyo virus disease...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPopulation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers